Table 3. Adherence to anti-hypertensive medications and risk of CVD event in the Pathways Heart Study.
| Outcome | MSM Parameter-ization | Person-Time | Reference Exposure* | %† | Non-reference Exposure* | %† | Super learner HR (95% CI)‡ |
|---|---|---|---|---|---|---|---|
| Heart Failure (n = 554) | 1 | 158,242 | CAA = 100% | 47 | CAA<100% | 53 | 1.47 (0.57–3.77) |
| 2 | 158,242 | CAA≥80% | 24 | CAA<80% | 76 | 1.46 (0.51–4.14) | |
| 3 | 158,242 | CAA = 100% | 24 | CAA<80% | 23 | 1.48 (0.52–4.21) | |
| 0.8≤CAA<100% | 53 | 1.42 (0.33–6.13) | |||||
| Ischemic Heart Disease (n = 438) | 1 | 154,243 | CAA = 100% | 47 | CAA<100% | 53 | 1.70 (0.73–3.95) |
| 2 | 154,243 | CAA≥80% | 24 | CAA<80% | 76 | 1.42 (0.52–3.83) | |
| 3 | 154,243 | CAA = 100% | 24 | CAA<80% | 23 | 1.51 (0.56–4.12) | |
| 80%≤CAA<100% | 53 | 2.43 (0.68–8.66) | |||||
| Stroke (n = 248) | 1 | 163,222 | CAA = 100% | 47 | CAA<100% | 53 | 0.30 (0.11–0.83) |
| 2 | 163,222 | CAA≥80% | 24 | CAA<80% | 76 | 0.36 (0.12–1.12) | |
| 3 | 163,222 | CAA = 100% | 24 | CAA<80% | 23 | 0.35 (0.11–1.08) | |
| 80%≤CAA<100% | 53 | 0.14 (0.03–0.57) | |||||
| All CVD (n = 921) | 1 | 144,569 | CAA = 100% | 46 | CAA<100% | 54 | 1.21 (0.58–2.54) |
| 2 | 144,569 | CAA≥80% | 24 | CAA<80% | 76 | 0.91 (0.37–2.23) | |
| 3 | 144,569 | CAA = 100% | 24 | CAA<80% | 22 | 0.96 (0.39–2.35) | |
| 80%≤CAA<100% | 54 | 2.50 (0.85–7.40) |
* Exposure level indicates a patient’s cumulative average adherence (CAA) up to the risk set that defines each hazard ratio (HR) and 95% confidence interval (CI)
† Proportion of cohort in exposed group
‡ Stabilized, truncated at 20, inverse probability weighting HR estimates. An HR>1 indicates that the non-reference exposure level is deleterious.